

Impact of Hormonal Therapies on Hemostasis

You are developing a new hormonal therapy, for instance a new combined oral contraceptive or an hormone replacement therapy?

QUALIblood provides a **comprehensive analytical package** to assess the impact of therapies on the hemostasis through the evaluation of **key biomarkers**.

Evaluation of traditional hemostasis biomarkers


PT	SHBG
aPTT	TGT
Protein C	FVIII
Free Protein S	Angiotensinogen
Anti-thrombin III	

FV-independent Activated Protein C resistance

nAPCsr

An innovative biomarker developed by QUALIblood to evaluate APC resistance induced by hormonal treatment. This biomarker has been developed to respond to the recommendation of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee*

*<https://doi.org/10.1016/j.jth.2022.10.014>



Evaluation of genetic mutations

FV Leiden
Prothrombin G20210A



Contact us if you need additional information or a quotation:
contact@qualiblood.eu

Your partner in precision bioanalysis
www.qualiblood.eu